Therapeutic Potential of Intranasal Drug Delivery in Preclinical Studies of Ischemic Stroke and Intracerebral Hemorrhage

2019 ◽  
pp. 27-42
Author(s):  
Qian Li ◽  
Claire F. Levine ◽  
Jian Wang
Keyword(s):  
Drug Delivery ◽  
Ischemic Stroke ◽  
Intracerebral Hemorrhage ◽  
Therapeutic Potential ◽  
Preclinical Studies ◽  
Intranasal Drug Delivery

scholarly journals Paving Luteolin Therapeutic Potentialities and Agro-Food-Pharma Applications: Emphasis on In Vivo Pharmacological Effects and Bioavailability Traits

2021 ◽  
Vol 2021 ◽  
pp. 1-20
Author(s):  
Yasaman Taheri ◽  
Javad Sharifi-Rad ◽  
Gizem Antika ◽  
Yakup Berkay Yılmaz ◽  
Tugba Boyunegmez Tumer ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Therapeutic Potential ◽  
Pharmacological Action ◽  
Biological Properties ◽  
Preclinical Studies ◽  
Pharmacological Effects ◽  
Naturally Occurring ◽  
Delivery Strategies ◽  
Pharmacological Potential

Luteolin is a naturally occurring secondary metabolite belonging to the class of flavones. As many other natural flavonoids, it is often found in combination with glycosides in many fruits, vegetables, and plants, contributing to their biological and pharmacological value. Many preclinical studies report that luteolin present excellent antioxidant, anticancer, antimicrobial, neuroprotective, cardioprotective, antiviral, and anti-inflammatory effects, and as a consequence, various clinical trials have been designed to investigate the therapeutic potential of luteolin in humans. However, luteolin has a very limited bioavailability, which consequently affects its biological properties and efficacy. Several drug delivery strategies have been developed to raise its bioavailability, with nanoformulations and lipid carriers, such as liposomes, being the most intensively explored. Pharmacological potential of luteolin in various disorders has also been underlined, but to some of them, the exact mechanism is still poorly understood. Given the great potential of this natural antioxidant in health, this review is aimed at providing an extensive overview on the in vivo pharmacological action of luteolin and at stressing the main features related to its bioavailability, absorption, and metabolism, while essential steps determine its absolute health benefits and safety profiles. In addition, despite the scarcity of studies on luteolin bioavailability, the different drug delivery formulations developed to increase its bioavailability are also listed here.

Abstract P768: Vascular Cellular Adhesion Molecule Targeting for the Treatment of Acute Neurovascular Inflammation

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Jia Nong ◽  
Oscar Armando Marcos-Contreras ◽  
Raisa Kiseleva ◽  
Patrick Glassman ◽  
Helene Descamps ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Ischemic Stroke ◽  
Adhesion Molecule ◽  
Targeted Drug Delivery ◽  
Therapeutic Potential ◽  
Cellular Adhesion ◽  
Therapeutic Effects ◽  
Cellular Adhesion Molecule ◽  
Delivery Strategies ◽  
Targeted Drug

Targeted drug delivery is an attractive strategy for treatment of life-threatening inflammatory brain pathologies such as ischemic stroke. In these conditions, adhesion molecule expression (e.g. vascular cellular adhesion molecule-1, VCAM) is upregulated on endothelium. Hence, VCAM represents a relevant target for selective drug delivery. We have utilized αVCAM monoclonal antibodies to target therapeutic proteins and nanocarriers (liposomes and lipid nanoparticles, LNPs) to the pathologically-altered vasculature.To assess tissue biodistribution and therapeutic effects of VCAM-targeted agents, we used 2 mouse models: 1) acute inflammation induced by intra-striatal injection of tumor necrosis factor-α (TNF), and 2) ischemic stroke induced by transient middle cerebral artery occlusion (tMCAO). Biodistribution was assayed by measuring radioactivity in blood and organs 30 minutes after injection. Efficacy was determined by tracing radiolabeled albumin extravasation to assess edema.The results showed that VCAM targeting was increased by TNF injection, and that targeting to VCAM enhanced the cerebral accumulation of αVCAM conjugated thrombomodulin (TM) and nanocarriers by orders of magnitude (Fig A). It is noteworthy that αVCAM-TM and free αVCAM antibody had similar levels of brain uptake. Our data also demonstrated the protective effect of αVCAM-liposome loaded with dexamethasone on brain edema (Fig B), indicating the therapeutic potential of VCAM-targeting drug delivery strategies. Further, the results in tMCAO model recapitulated our findings in the TNF model that targeting to VCAM significantly improves delivery to the ischemic brain (Fig C). In summary, we have shown that targeting VCAM permits delivery of a diverse array of therapeutics to the inflamed vasculature in conditions such as ischemic stroke. Future work will focus on evaluating the therapeutic properties of VCAM-targeted drug delivery strategies.

Recent In Vitro and In Silico Advances in the Understanding of Intranasal Drug Delivery

2020 ◽  
Vol 26 ◽  
Author(s):  
John Chen ◽  
Andrew Martin ◽  
Warren H. Finlay
Keyword(s):  
Drug Delivery ◽  
In Silico ◽  
Local Drug Delivery ◽  
In Vivo Studies ◽  
Intranasal Drug Delivery ◽  
Nasal Sprays ◽  
In Silico Studies ◽  
Drug Delivery Devices

Background: Many drugs are delivered intranasally for local or systemic effect, typically in the form of droplets or aerosols. Because of the high cost of in vivo studies, drug developers and researchers often turn to in vitro or in silico testing when first evaluating the behavior and properties of intranasal drug delivery devices and formulations. Recent advances in manufacturing and computer technologies have allowed for increasingly realistic and sophisticated in vitro and in silico reconstructions of the human nasal airways. Objective: To perform a summary of advances in understanding of intranasal drug delivery based on recent in vitro and in silico studies. Conclusion: The turbinates are a common target for local drug delivery applications, and while nasal sprays are able to reach this region, there is currently no broad consensus across the in vitro and in silico literature concerning optimal parameters for device design, formulation properties and patient technique which would maximize turbinate deposition. Nebulizers are able to more easily target the turbinates, but come with the disadvantage of significant lung deposition. Targeting of the olfactory region of the nasal cavity has been explored for potential treatment of central nervous system conditions. Conventional intranasal devices, such as nasal sprays and nebulizers, deliver very little dose to the olfactory region. Recent progress in our understanding of intranasal delivery will be useful in the development of the next generation of intranasal drug delivery devices.

The Potential of Milk-derived Exosomes for Drug Delivery

2020 ◽  
Vol 17 ◽  
Author(s):  
Shuyuan Li ◽  
Yue Tang ◽  
Yushun Dou
Keyword(s):  
Drug Delivery ◽  
Oral Delivery ◽  
Therapeutic Potential ◽  
Current Knowledge ◽  
Biological Fluids ◽  
Drug Loading ◽  
Drug Carriers ◽  
Current Application ◽  
Therapeutic Benefits ◽  
Loading Methods

Background: Exosomes, one of the extracellular vesicles, are widely present in all biological fluids and play an important role in intercellular communication. Because of its hydrophobic lipid bilayer and aqueous hydrophilic core structure, it is considered a possible alternative to liposome drug delivery systems. Not only do they protect the cargo like liposomes during delivery, they are less toxic and better tolerated. However, due to the lack of sources and methods for obtaining enough exosomes, the therapeutic application of exosomes as drug carriers is limited. Methods: A literature search was performed using the ScienceDirect and PubMed electronic databases to obtain information from published literature on milk exosomes related to drug delivery. Results: Here, we briefly reviewed the current knowledge of exosomes, expounded the advantages of milk-derived exosomes over other delivery vectors, including a higher yield, the oral delivery characteristic and additional therapeutic benefits. The purification and drug loading methods of milk exosomes, and the current application of milk exosomes were also introduced. Conclusion: The emergence of milk-derived exosomes is expected to break through the limitations of exosomes as therapeutic carriers of drugs. We hope to raise awareness of the therapeutic potential of milk-derived exosomes as a new drug delivery system.

Therapeutic Potential of Endothelial Colony Forming Cells Derived from Human Umbilical Cord Blood

2019 ◽  
Vol 14 (6) ◽  
pp. 460-465 ◽  
Author(s):  
Jing Jia ◽  
Baitao Ma ◽  
Shaoshuai Wang ◽  
Ling Feng
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Tissue Regeneration ◽  
Umbilical Cord Blood ◽  
Therapeutic Potential ◽  
Human Umbilical Cord Blood ◽  
Proliferative Potential ◽  
Human Umbilical Cord ◽  
Preclinical Studies ◽  
Endothelial Colony Forming Cells

Endothelial progenitor cells (EPCs) are implicated in multiple biologic processes such as vascular homeostasis, neovascularization and tissue regeneration, and tumor angiogenesis. A subtype of EPCs is referred to as endothelial colony-forming cells (ECFCs), which display robust clonal proliferative potential and can form durable and functional blood vessels in animal models. In this review, we provide a brief overview of EPCs’ characteristics, classification and origins, a summary of the progress in preclinical studies with regard to the therapeutic potential of human umbilical cord blood derived ECFCs (CB-ECFCs) for ischemia repair, tissue engineering and tumor, and highlight the necessity to select high proliferative CB-ECFCs and to optimize their recovery and expansion conditions.

Sign in / Sign up

Export Citation Format

Share Document